1 / 5

targetncer

http://target.cancer.gov. Areas for TARGET Initiative Research Focus. Underlying premise: Genes that are altered in expression, copy number, or LOH and mutation will highlight cellular pathways for therapeutic exploitation Approach:

gordon
Télécharger la présentation

targetncer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. http://target.cancer.gov

  2. Areas for TARGET Initiative Research Focus Underlying premise: Genes that are altered in expression, copy number, or LOH and mutation will highlight cellular pathways for therapeutic exploitation Approach: • High-throughput array-based technologies to comprehensively characterize genomic and transcriptomic profiles • Gene resequencing to identify genes that are consistently altered in specific childhood cancers • Functional validation to validate putative therapeutic targets

  3. Cancer TARGET Initiative Strategy for ALL and Neuroblastoma Projects Disease Expertise – COG Disease Committee Genomic Characterization Expertise Gene Sequencing Expertise Transcriptomic Characterization Expertise Clinical Specimens

  4. Speakers for the ALL and Neuroblastoma TARGET Teams • Stephen P. Hunger, MD (ALL TARGET) • Professor and Ergen Family Chair in Pediatric Cancer • Director, Center for Cancer and Blood Disorders • Chief, Pediatric Hematology/Oncology/BMT • University of Colorado Denver and The Children’s Hospital • Chair, COG ALL Committee • John M. Maris, MD (Neuroblastoma TARGET) • Giulio D'Angio Associate Professor of Pediatrics • Chief, Division of Oncology • Director, Center for Childhood Cancer Research • Children's Hospital of Philadelphia • University of Pennsylvania School of Medicine • Chair, COG Neuroblastoma Committee

  5. Identifying More Effective Treatments for Children with Cancer TARGET Discovery Programs Pediatric Preclinical Testing Phase 1 Clinical Trial (COG, NANT, PBTC, CCR) COG Definitive Clinical Trial

More Related